# Vactosertib in Combination with Pembrolizumab in Metastatic Colorectal or Gastric Cancer

> **NCT03724851** · PHASE1,PHASE2 · COMPLETED · sponsor: **MedPacto, Inc.** · enrollment: 120 (actual)

## Conditions studied

- Metastatic Colorectal Cancer
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** TEW-7197

## Key facts

- **NCT ID:** NCT03724851
- **Lead sponsor:** MedPacto, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-20
- **Primary completion:** 2024-05-07
- **Final completion:** 2024-05-07
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2025-03-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03724851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03724851, "Vactosertib in Combination with Pembrolizumab in Metastatic Colorectal or Gastric Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03724851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*